Bromfenac bioavailability
AssigneeBausch & Lomb Pharma Holdings Corp.
InventorsAngel Padilla, George Baklayan
Life of this patent
Estimating the term…
Abstract
Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY™ formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.
Claims23
A method for enhancing ocular bioavailability of bromfenac in an aqueous solution topically administered to an eye of a patient in need thereof, the method comprising topically ocularly administering a bromfenac formulation at pH between pH≧6.0 and pH<8.3 to a patient in need thereof, resulting in enhanced bromfenac bioavailability in ocular tissue compared to the same formulation at pH≧8.3.
A method for treating a patient in need thereof with bromfenac as a free acid, the method comprising topically ocularly administering a bromfenac formulation having pH between pH≧6.0 and pH<8.3 and bromfenac between ≧0.02% and <0.20% to a patient in need thereof, resulting in at least equal bromfenac efficacy as bromfenac 0.09%, pH 8.3.
An aqueous composition formulated for topical ocular administration, the composition comprising bromfenac at a concentration >0.02% and <0.20%, as free acid, in a formulation with at least one biocompatible excipient and buffered at a pH between pH≧6.0 and pH<8.3.
Dependencies are inferred from the claim text.